Capivasertib Patent Expiration
Capivasertib is used for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer with specific genetic alterations after progression on endocrine therapy in the metastatic setting or recurrence within 12 months of adjuvant therapy. It was first introduced by Astrazeneca Pharmaceuticals Lp
Capivasertib Patents
Given below is the list of patents protecting Capivasertib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Truqap | US10039766 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide | Apr 16, 2033 | Astrazeneca |
| Truqap | US9487525 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | Apr 16, 2033 | Astrazeneca |
| Truqap | US8101623 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | Mar 10, 2030 | Astrazeneca |
| Truqap | US10059714 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US10654855 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US11236095 | Protein Kinase B Inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US11760760 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US12252495 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US9492453 | Protein Kinase B Inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US8809336 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
Oct 25, 2025
(Expired) | Astrazeneca |
| Truqap | US9006430 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
Oct 25, 2025
(Expired) | Astrazeneca |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Capivasertib's patents.
Latest Legal Activities on Capivasertib's Patents
Given below is the list recent legal activities going on the following patents of Capivasertib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jan, 2026 | US10039766 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jan, 2026 | US10059714 |
| transaction for FDA Determination of Regulatory Review Period | 20 Jun, 2025 | US8101623 |
| transaction for FDA Determination of Regulatory Review Period | 20 Jun, 2025 | US10059714 |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2025 | US8101623 |
| Information Disclosure Statement (IDS) Filed | 02 May, 2025 | US8101623 |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2025 | US10059714 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US10059714 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US8101623 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8101623 |
Capivasertib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Capivasertib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
